These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 32348223)

  • 1. Current Status of Drug Targets and Emerging Therapeutic Strategies in the Management of Alzheimer's Disease.
    Ghosh S; Durgvanshi S; Agarwal S; Raghunath M; Sinha JK
    Curr Neuropharmacol; 2020; 18(9):883-903. PubMed ID: 32348223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing Aβ load and tau phosphorylation: Emerging perspective for treating Alzheimer's disease.
    Kalra J; Khan A
    Eur J Pharmacol; 2015 Oct; 764():571-581. PubMed ID: 26209363
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological Treatment of Alzheimer's Disease: Insights from
    Cheng X; Song C; Du Y; Gaur U; Yang M
    Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32610577
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insights into the Pathophysiology of Alzheimer's Disease and Potential Therapeutic Targets: A Current Perspective.
    Rajah Kumaran K; Yunusa S; Perimal E; Wahab H; Müller CP; Hassan Z
    J Alzheimers Dis; 2023; 91(2):507-530. PubMed ID: 36502321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alzheimer's disease: emerging trends in small molecule therapies.
    Mohamed T; Rao PP
    Curr Med Chem; 2011; 18(28):4299-320. PubMed ID: 21861820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NMDA neurotransmission dysfunction in mild cognitive impairment and Alzheimer's disease.
    Lin CH; Huang YJ; Lin CJ; Lane HY; Tsai GE
    Curr Pharm Des; 2014; 20(32):5169-79. PubMed ID: 24410566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synaptic dysfunction in Alzheimer's disease: Mechanisms and therapeutic strategies.
    Chen Y; Fu AKY; Ip NY
    Pharmacol Ther; 2019 Mar; 195():186-198. PubMed ID: 30439458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cholinergic system in aging and neuronal degeneration.
    Schliebs R; Arendt T
    Behav Brain Res; 2011 Aug; 221(2):555-63. PubMed ID: 21145918
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amyloid cascade hypothesis: Pathogenesis and therapeutic strategies in Alzheimer's disease.
    Barage SH; Sonawane KD
    Neuropeptides; 2015 Aug; 52():1-18. PubMed ID: 26149638
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of the N-methyl-D-aspartate receptor in Alzheimer's disease: therapeutic potential.
    Doraiswamy PM
    Curr Neurol Neurosci Rep; 2003 Sep; 3(5):373-8. PubMed ID: 12914679
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advances in recent patent and clinical trial drug development for Alzheimer's disease.
    Liu H; Wang L; Su W; Xie XQ
    Pharm Pat Anal; 2014 Jul; 3(4):429-47. PubMed ID: 25291315
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of Cholinergic, Adrenergic, and Glutamatergic Network Modulation with Cognitive Dysfunction in Alzheimer's Disease.
    Cheng YJ; Lin CH; Lane HY
    Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33668976
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tau therapeutics for Alzheimer's disease: the promise and the challenges.
    Gold M
    J Mol Neurosci; 2002 Dec; 19(3):331-4. PubMed ID: 12540060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on Alzheimer's Disease Therapy and Prevention Strategies.
    Graham WV; Bonito-Oliva A; Sakmar TP
    Annu Rev Med; 2017 Jan; 68():413-430. PubMed ID: 28099083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multifaceted Alzheimer's Disease: Building a Roadmap for Advancement of Novel Therapies.
    Kaur D; Behl T; Sehgal A; Singh S; Sharma N; Bungau S
    Neurochem Res; 2021 Nov; 46(11):2832-2851. PubMed ID: 34357520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular Insight into the Therapeutic Promise of Flavonoids against Alzheimer's Disease.
    Uddin MS; Kabir MT; Niaz K; Jeandet P; Clément C; Mathew B; Rauf A; Rengasamy KRR; Sobarzo-Sánchez E; Ashraf GM; Aleya L
    Molecules; 2020 Mar; 25(6):. PubMed ID: 32168835
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic perspectives of drugs targeting Toll-like receptors based on immune physiopathology theory of Alzheimer's disease.
    Schneider AR; Sari Y
    CNS Neurol Disord Drug Targets; 2014; 13(5):909-20. PubMed ID: 25012616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current treatment for Alzheimer disease and future prospects.
    Tariot PN; Federoff HJ
    Alzheimer Dis Assoc Disord; 2003; 17 Suppl 4():S105-13. PubMed ID: 14512816
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current Status of Alzheimer's Disease and Pathological Mechanisms Investigating the Therapeutic Molecular Targets.
    Bagga S; Kumar M
    Curr Mol Med; 2023; 23(6):492-508. PubMed ID: 35379149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanism of Oxidative Stress and Synapse Dysfunction in the Pathogenesis of Alzheimer's Disease: Understanding the Therapeutics Strategies.
    Kamat PK; Kalani A; Rai S; Swarnkar S; Tota S; Nath C; Tyagi N
    Mol Neurobiol; 2016 Jan; 53(1):648-661. PubMed ID: 25511446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.